Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M. Khanani, Francisco J. Rodríguez, Jordi Monés et al.|The Lancet|2023Cited by 343
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALECharles C. Wykoff, Caroline R. Baumal, Dilsher S. Dhoot et al.|American Journal of Ophthalmology|2025Cited by 19